Retrospective study of a cohort of adult patients with hematological malignancies in a tropical area

Table 3 Characteristics, treatment and evolution of adult T-cell lymphoma-leukemia/lymphoma/leukemia

No.	Gender	Age	Stage	Tumor sites	Regimen 1	Regimen 2	Regimen 3	FU
ATL/lymphoma
1	M	28	NA		L/Z + P-IFN + oral ETO	CHOP	0	2
2	M	34	IV		L/Z + P-IFN	CHOP	DHAP	3
3	M	38	NA		L/Z + P-IFN	CHOP	DHAP	1
4	F	46	III	Abdomen, Ca2+		CHOP	VBl	1
5	M	49	IV			CHOP	DHAP	< 1
6	M	49	IV	Colon, CNS	L/Z + P-IFN	CHOP	IT-MTX	< 1
7	F	51	IE	Nasal, sinus	0	CHOP	0	< 1
8	F	58	IIA		L/Z + P-IFN	CHOP	0	3
9	F	62	NA		L/Z + P-IFN + ETO oral	CHOP	0	5
10	M	42	IV	Ca2+	R-CHOP	0	0	3
ATL/leukemia
10	M	41	-	Liver, cavum	L/Z + P-IFN	CHOP	0	< 1
11	F	47	-		L/Z + P-IFN + oral ETO	CHOP	0	4

Hydroxydaunorubicine, oncovin^®, prednisone; M: Male; F: Female; age in years; stage according to Ann Arbor staging system; ATL: Adult T-cell lymphoma-leukemia; FU: Follow-up in years; Ca²⁺: Hypercalcemia; CNS: Central nervous system; L/Z: Lamivudin + Zidovudin; P-IFN: Peg-interferon α-2a; ETO: Etoposide; CHOP: Cyclophosphamide, R-CHOP: Rituximab-cyclophosphamide; DHAP: Dexamethasone, aracytine, cisplatin; VBl: Vinblastine; IT-MTX: Intra-thecal methotrexate; NA: Not available.